Myelodysplastic syndrome treatment with danazol and cis‐retinoic acid

Louis Letendre, Ralph Levitt, Robert V. Pierre, Georgene Schroeder, James A. Krook, James E. Mailliard, Roscoe F. Morton, Loren K. Tschetter
In: American Journal of Hematology · 1995 · vol. 48(4) , pp. 233–236 · doi:10.1002/ajh.2830480405 · PMID:7717370 · W2102299347
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

We prospectively treated 46 patients with favorable myelodysplastic syndrome classified as refractory anemia (RA), refractory cytopenia (RC), or refractory anemia with ringed sideroblasts (RARS). These patients received one of two schedules of 13-Cis-Retinoic Acid (low dose 80 mg daily for 6 months vs. high dose 200 mg po daily for 3 months), or Danazol (800 mg po daily for 3 months), and were crossed over to the alternative drug in the absence of response or at progression. Using strict criteria of response we found little objective evidence of activity for either compound. Only two minor responses were seen among 22 patients treated with low dose 13-CRA, 1 response among 20 cases that received high dose 13-CRA, and 1 partial response and 1 minor response to Danazol among 34 cases. Neither 13-Cis-Retinoic Acid nor Danazol appear active enough in patients with favorable myelodysplastic syndrome to justify their use.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (5)

Source provenance

openalex
last seen: 2026-05-11T05:56:47.744056+00:00
unpaywall
last seen: 2026-06-06T02:00:05.402940+00:00
License: CC0 · commercial use OK